Rocket Lab's Insider Sales Tell a Story That Isn't There

Rocket Lab insider sales were tax-related, not a signal. Q2 revenue rose 62% to $234M, but Neutron delays and Iridium deal risks loom.

The most scrutinized insider transactions at Rocket Lab this month weren't a signal — they were a tax bill. When five executives unloaded shares worth millions on August 24, followed by another 41,592 shares from Frank Klein and Arjun Kampani a week later, the filings looked like a management vote of no confidence. Almost all were declared "sell-to-cover" — non-discretionary sales to settle tax obligations from vesting restricted stock units, largely executed under pre-arranged Rule 10b5-1 plans.

COO Frank Klein disposed of 45,692 shares for $3.18 million on August 24, while President Marvin Bradford Clevenger sold 15,051 shares for roughly $1.05 million and CFO Adam Spice offloaded 9,677 shares for $674,000. These are mechanical events triggered by vesting schedules, not spontaneous decisions born of concern about the business trajectory.

The Operating Picture Tells a Different Story

Rocket Lab's second quarter delivered revenue of $234 million — up 62 percent year-over-year and 17 percent sequentially. The backlog ballooned 137 percent over twelve months to approximately $2.4 billion, with new orders exceeding $1 billion landing in the quarter alone, including a $397 million agreement with the Space Force. Management guided third-quarter revenue to between $250 million and $265 million.

The regulatory front has been equally productive. The antitrust waiting period for the roughly $8 billion Iridium acquisition lapsed on August 12, the company filed its S-4 registration statement with the SEC, and it submitted applications to the FCC for transferring Iridium's licenses. Iridium shareholders vote on the deal on September 24 — and Rocket Lab's shares have slipped just 0.9 percent since, suggesting the market had already priced in the transaction's completion.

Reading the Fine Print on the Space Force Win

Mid-August brought news of Rocket Lab's inclusion in the NITE-STAR contract vehicle from the US Space Force — a framework worth $981 million for space testing and training infrastructure. The caveat: that total is split among multiple contractors. Rocket Lab is now eligible to bid on individual task orders, making this a door-opener rather than guaranteed revenue. It's a distinction worth keeping in mind when assessing the headline.

The quarterly results themselves were mixed. A 41.5 percent GAAP-adjusted gross margin accompanied an adjusted EBITDA loss of $8.8 million, and media reports indicated revenue missed expectations. Management countered that more than $1 billion in contracts had been signed since quarter-end — evidence that demand remains intact even if converting orders to revenue takes time.

Neutron Remains the Lingering Risk

The launch vehicle that could define Rocket Lab's next chapter is also its biggest uncertainty. Bloomberg reported that the company signaled a potential new delay for the Neutron rocket in early August: delivery to the launch pad is targeted for the fourth quarter, but management avoided committing to a launch this year, making a 2027 debut increasingly plausible. For a company whose valuation depends on growth beyond the Electron program, that's a genuine concern.

The company did notch its 93rd Electron mission on August 20 — the 14th of the year and the ninth successful QPS-SAR delivery for Japanese Earth-observation customer iQPS. That cadence demonstrates industrial-scale launch capability, something few competitors can match.

A Stock That's Testing Investors' Patience

The share price tells a more cautious tale. Trading at €55.10, the stock sits roughly 59 percent below its 52-week high of €133.80 and 18 percent under its 50-day moving average. Over twelve months, however, it's still up 33 percent — the recent correction looks less dramatic against that longer horizon.

Institutional interest persists despite the weakness: Capstone Investment Advisors built a new position worth $1.56 million during the second quarter.

Rocket Lab embodies the broader New Space dilemma — companies delivering technologically while profitability remains elusive, in a market increasingly impatient with that trade-off. The insider sales are noise; the real signals to watch are Neutron's next milestones and whether the Iridium deal closes as scheduled. The stock's 19 percent discount to its 50-day average of €67.16 reflects skepticism about the recent news flow — but whether that skepticism is warranted will be answered by operational execution, not insider filings.